Edesa Biotech to Participate in Upcoming Dermatology Meetings

Edesa Biotech, Inc., a biopharmaceutical company in the clinical-stage, has announced its plans to attend two significant dermatology events in March 2024. The company, known for its work on therapeutics for immuno-inflammatory diseases, aims to join the American Contact Dermatitis Society Annual Meeting on March 7, followed by the American Academy of Dermatology Annual Meeting from March 8-12, 2024, in San Diego, California. This participation reflects Edesa's commitment to advancing the conversation around treatments for dermatological conditions.

Interested attendees can arrange meetings with Edesa by reaching out via email. This initiative underlines the company’s aspirations to foster connections within the dermatology community. Edesa's portfolio includes promising treatments for various conditions, with projects ranging from a monoclonal antibody for Acute Respiratory Distress Syndrome in a Phase 3 study to a Phase 2 trial-approved treatment for vitiligo, and a topical treatment for Allergic Contact Dermatitis in development stages.